ReviewIJTLD open2025
TB elimination in Southern Africa: overview and critical reflection.
Review in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Targeted next-generation sequencing implementation in Eswatini identifies rifampicin and bedaquiline resistance undetected by routine diagnostic testing.Nature communications · 2026Article
- Multilevel Determinants of Tuberculosis Treatment Interruption in Rural South Africa: Insights from Primary Healthcare Nurses.International journal of environmental research and public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite significant progress, TB remains a major public health challenge in Southern Africa. We highlight the key initiatives in Eswatini, Mozambique and South Africa, which have implemented various interventions, including systematic TB screening, TB preventive treatment, targeted next-generation sequencing, targeted universal testing, and shorter drug-resistant and paediatric TB regimens. We also identify the key challenges, such as inconsistent drug access, increasing drug resistance and limited healthcare capacity, which continue to affect progress. Health systems must also balance TB care with broader healthcare priorities, and the integration of TB care into existing services requires further investment in outreach, treatment support and training. Identifying and treating missing people with TB, diagnosing TB in children, and improving treatment adherence remain critical areas requiring enhanced support and resources. While new diagnostic tools and treatments offer promise, their high costs and labour demands present barriers to routine implementation. Successful TB elimination will depend on simple, low-cost prevention, testing and treatment options, tailored to each country's specific needs. All of which will require sustained political commitment, innovation and strategic investments in health system strengthening and community-based care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.